Therapeutic treatment with the anti-inflammatory drug candidate MW151 may partially reduce memory impairment and normalizes hippocampal metabolic markers in a mouse model of comorbid amyloid and vascular pathology

Alzheimer’s disease (AD) is the leading cause of dementia in the elderly, but therapeutic options are lacking. Despite long being able to effectively treat the ill-effects of pathology present in various rodent models of AD, translation of these strategies to the clinic has so far been disappointing...

Descripción completa

Detalles Bibliográficos
Autores principales: Braun, David J., Powell, David K., McLouth, Christopher J., Roy, Saktimayee M., Watterson, D. Martin, Van Eldik, Linda J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791470/
https://www.ncbi.nlm.nih.gov/pubmed/35081152
http://dx.doi.org/10.1371/journal.pone.0262474

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791470/
https://www.ncbi.nlm.nih.gov/pubmed/35081152
http://dx.doi.org/10.1371/journal.pone.0262474

Ejemplares similares